|Day Low/High||7.35 / 8.20|
|52 Wk Low/High||4.63 / 9.91|
Collaboration combines Pfizer's heritage in Rare Disease, capabilities in gene therapy, and expertise in hemophilia with Sangamo's deep knowledge in genomic therapies
Aratana Therapeutics, Trevena and Sangamo Therapeutics were among the biotech stock movers in premarket trading on Thursday.
Rare Pediatric Disease Designation for SB-913 In Vivo Genome Editing Treatment for MPS II
Vertex Pharmaceuticals, Sangamo Therapeutics and Depomed were among the biotech stock movers in premarket trading on Wednesday.
Engineered Zinc Finger Protein Transcription Factors Lowered Tau Levels by More Than 90% in Human Neurons In Vitro and Reduced Neuritic Dystrophy in Amyloid Mouse Model of Alzheimer's Disease
Investors eyeing a purchase of Sangamo Therapeutics Inc stock, but tentative about paying the going market price of $4.18/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $3 strike, which has a bid at the time of this writing of 50 cents.
Kathy Yi Appointed to Succeed H. Ward Wolff as CFO Upon His Retirement in March
BioCryst Pharmaceuticals, Sangamo Therapeutics and Cempra were among the biotech stock movers in premarket trading on Monday.
Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.
Impax Laboratories, Sangamo Therapeutics and Aralez Pharmaceuticals are among the premarket movers in biotech.
- New architectures enable targeting of any chosen location in the genome with very high precision
Clear strategy with new management, organizational structure and clinical capabilities will drive Sangamo's industry-leading scientific platform into human studies
SB-525 is one of four programs in the Company's newly focused clinical portfolio of in vivo genomic therapies for rare diseases
On Track to File Investigational New Drug Application for Hemophilia A Program by End of 2016
Dr. Edward Conner Appointed as Senior Vice President and Chief Medical Officer and Curt Herberts Promoted to Newly Created Role of Senior Vice President and Chief Business Officer
ZFN-Mediated Genome Editing Programs in Sickle Cell Disease and Beta-Thalassemia Will Move from Biogen to Bioverativ in Line with the Spin-Off Company's Focus on Rare Blood Disorders